Attempts to introduce a tougher new definition of counterfeit medicines at the World Health Organization have so far been stalled by opposition from the Indian government, supported by other Asian countries. The change from the current terminology has been pushed by the International Medical Products Anti-Counterfeiting Taskforce, a WHO unit established in 2006. A compromize emphasizing the issue of substandard drugs is favored by the government, while the Drug Comptroller General of India, Surinder Singh, is reported to be working on a new domestic definition of counterfeits to take effect by the end of the year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze